Tech Company Financing Transactions
Lacerta Therapeutics Funding Round
Sarepta Therapeutics invested in a $30 million funding round for Lacerta Therapeutics. The financing round was announced by the company on 8/13/2018.
Transaction Overview
Company Name
Announced On
8/13/2018
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Undisclosed
Investors
Sarepta Therapeutics (Douglas Ingram)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12085 Research Dr. 46
Alachua, FL 32615
USA
Alachua, FL 32615
USA
Phone
Undisclosed
Website
Email Address
Overview
Lacerta Therapeutics is a clinical-stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. We are advancing our clinical programs using proprietary capsid variants and a scalable vector manufacturing platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joseph Reddy
Chief Technical Officer
Kenneth Warrington
Browse more venture capital transactions:
Prev: 8/13/2018: Teamleader venture capital transaction
Next: 8/13/2018: Tizeti venture capital transaction
Share this article
Where The Data Comes From
We document funding rounds that are announced publicly. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs